Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Spravato, Depression
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
BioSpace
5d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
FiercePharma
5d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Boing Boing on MSN
2d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Los Angeles wildfire updates
SK plane crash probe
Immigration raids across TX
Swaps Pepsi for Coca-Cola
Texas nightclub shooting
Graham on Jan. 6 pardons
‘Flight Risk’ tops box office
Colombia tariffs paused
Belarus releases US citizen
Lilleberg faces NHL hearing
Israel permits Gaza return
Proposes TikTok merger
To limit public schedule
New OC for Seahawks
Emil Bove visits Chicago
PETA activists arrested
Indicted for insurrection
Chiefs beat Bills
Sinner wins Australian Open
DOJ drops case
Confirmed as DHS secretary
Sentenced to 17+ years
US lifts bomb restrictions
38 hurt on United flight
NK tested cruise missiles?
Eagles defeat Commanders
Israel, Lebanon extend truce
Recalls over 80,000 SUVs
Shifts view on COVID origins
Hack impacted 190M
Feedback